Vera Therapeutics, Inc. (VERA)

NASDAQ: VERA · IEX Real-Time Price · USD
19.35
-0.22 (-1.12%)
Aug 11, 2022 4:00 PM EDT - Market closed
-1.12%
Market Cap 525.19M
Revenue (ttm) n/a
Net Income (ttm) -44.98M
Shares Out 27.14M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 52,625
Open 19.57
Previous Close 19.57
Day's Range 18.48 - 19.61
52-Week Range 12.29 - 37.11
Beta n/a
Analysts Buy
Price Target 42.40 (+119.1%)
Earnings Date Aug 15, 2022

About VERA

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode... [Read more...]

Industry Biotechnology
IPO Date May 14, 2021
Employees 18
Stock Exchange NASDAQ
Ticker Symbol VERA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for VERA stock is "Buy." The 12-month stock price forecast is 42.4, which is an increase of 119.12% from the latest price.

Price Target
$42.4
(119.12% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

BRISBANE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pat...

Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare Conference

BRISBANE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pat...

Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of Ig...

Topline results anticipated fourth quarter of 2022 Topline results anticipated fourth quarter of 2022

Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidne...

BRISBANE, Calif., June 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pat...

Vera Therapeutics to Participate in the 2022 Jefferies Healthcare Conference

BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pat...

Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal ...

BRISBANE, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pati...

Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results

BRISBANE, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pati...

Vera Therapeutics to Present at Upcoming Conferences in May 2022

BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pati...

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Tra...

BRISBANE, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pati...

Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients...

BRISBANE, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pati...

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D.

BRISBANE, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients...

Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

BRISBANE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pa...

Vera Therapeutics to Host BK Virus Webinar Featuring Stanley C. Jordan, M.D.

Management to provide overview of MAU868, its lead asset in the treatment of BK Virus infections in kidney transplant patients

Vera Therapeutics to Host Business Update Call

BRISBANE, Calif., March 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for pa...

Vera Therapeutics to Participate in the 42nd Annual Cowen Health Care Conference

BRISBANE, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments fo...

Vera Therapeutics Announces Closing of Upsized Public Offering of Class A Common Stock and Full Exercise of Underwrit...

BRISBANE, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients ...

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”) (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatment...

Vera Therapeutics Announces Commencement of Public Offering of Class A Common Stock

BRISBANE, Calif., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients ...

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN - - Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -

Vera Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

BRISBANE, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for...

Vera Therapeutics (VERA) Sees Hammer Chart Pattern: Time to Buy?

Vera Therapeutics (VERA) has been struggling lately, but the selling pressure may be coming to an end soon.

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

Ongoing Phase 2 clinical trial for MAU868 in kidney transplant patients; potential first-in-class

Vera Therapeutics Announces Appointment of Kimball Hall to Board of Directors

Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufacturing experience Pharmaceutical industry leader brings more than 30 years of quality, regulatory and manufactu...

Vera Therapeutics to Present at Upcoming Investment Conferences in November 2021

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing and commercializing transformative tre...

Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases ...